<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-783
Date of Submission: 2024-09-08

This report was submitted by a Patient from Larsen-Davis Medical Center concerning patient ANON-PX-5182. The subject is an adult female with a significant medical history including migraines, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Subcutaneous route at a dosage of 425mg, initiated on 2024-06-12 for Hypercholesterolemia with the course ongoing; Omeprazole (Proton-pump inhibitor) administered via the Intravenous route at a dosage of 10mg, initiated on 2024-06-12 for Gastroesophageal reflux disease with the course ongoing.

On approximately 2024-06-30, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Nausea, Dizziness. The Vomiting was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed source and advised see. The current patient status regarding this symptom is 'Recovering'. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Dizziness was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Effect energy management most experience.</data>
report_id: ADR-2024-783
report_date: '2024-09-08'
patient_details:
  patient_id: ANON-PX-5182
  gender: Female
  relevant_history:
  - migraines
  - hypertension
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 425mg
  route_of_administration: Subcutaneous
  start_date: '2024-06-12'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
- drug_name: Omeprazole
  dosage: 10mg
  route_of_administration: Intravenous
  start_date: '2024-06-12'
  indication_for_use: Gastroesophageal reflux disease
  drug_class: Proton-pump inhibitor
adverse_reactions:
- symptom_name: Vomiting
  onset_date: '2024-06-30'
  severity: Moderate
  outcome: Recovering
  intervention_required: true
  intervention_details: Prescribed source and advised see.
- symptom_name: Nausea
  onset_date: '2024-06-30'
  severity: Mild
  outcome: Recovering
  intervention_required: false
- symptom_name: Dizziness
  onset_date: '2024-06-30'
  severity: Moderate
  outcome: Fatal
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Not applicable
reporting_facility: Larsen-Davis Medical Center
reporter_type: Patient
notes: Effect energy management most experience.
